Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NGM

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

NGM Biopharmaceuticals logo

About NGM Biopharmaceuticals Stock (NASDAQ:NGM)

Advanced Chart

Key Stats

Today's Range
$1.54
$1.54
50-Day Range
$1.52
$1.63
52-Week Range
$0.60
$4.69
Volume
N/A
Average Volume
1.47 million shs
Market Capitalization
$128.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NGM Biopharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

NGM MarketRank™: 

NGM Biopharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 787th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for NGM Biopharmaceuticals.

  • Earnings Growth

    Earnings for NGM Biopharmaceuticals are expected to grow in the coming year, from ($0.93) to ($0.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NGM Biopharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for NGM.
  • Dividend Yield

    NGM Biopharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NGM Biopharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for NGM.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for NGM Biopharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, NGM Biopharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.90% of the stock of NGM Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.74% of the stock of NGM Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NGM Biopharmaceuticals' insider trading history.
Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NGM Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

NGM Stock Analysis - Frequently Asked Questions

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.03. The firm had revenue of $18.58 million for the quarter, compared to analyst estimates of $18.90 million. NGM Biopharmaceuticals had a negative net margin of 3,223.34% and a negative trailing twelve-month return on equity of 77.85%.

NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that NGM Biopharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and PayPal (PYPL).

Company Calendar

Last Earnings
11/04/2021
Today
7/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NGM
Fax
N/A
Employees
138
Year Founded
1998

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$142.38 million
Net Margins
-3,223.34%
Pretax Margin
-3,223.34%

Debt

Sales & Book Value

Annual Sales
$4.42 million
Price / Cash Flow
N/A
Book Value
$1.80 per share
Price / Book
0.86

Miscellaneous

Free Float
53,499,000
Market Cap
$128.53 million
Optionable
Optionable
Beta
1.27

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:NGM) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners